Inflammatory Targets in IBD

Novel inflammatory targets are already being exploited in the management of IBD while a significant number are currently under investigation. This section of the Knowledge Centre describes the inflammatory targets currently used in the clinic as well as those at an advanced stage of development in the search for improved ulcerative colitis and Crohn’s disease therapies.

Interleukin 12/23

Interleukin 12/23

Read about interleukins-12 and -13 and how they can produce pro-inflammatory responses through the JAK signalling pathway.

Integrin and MAdCAM

Integrin and MAdCAM

Learn how integrins on the surface of leucocytes can facilitate "immune cell homing". How can this process be targeted by treatment?

Janus Family Kinase

Janus Family Kinase

Discover how JAKs are involved in a variety of processes, including immunity, with different cytokines signalling through different JAK members to modulate immune responses.

SMAD7

SMAD7

Find out why the overexpression of SMAD7 can cause inflammation in IBD through its relationship with TGF-β1.

Sphingosine 1-phosphate

Sphingosine 1-phosphate

Learn how sphingosine 1-phosphate binding to S1P1 can lead to lymphocyte release, contributing to gut inflammation.

Tumour Necrosis Factor Alpha

Tumour Necrosis Factor Alpha

Learn how this cytokine has become the target of standard therapies due to its role as one of the main pro-inflammatory agents in IBD.